-
AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial
A study designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder.
Trial is open for enrollment
View All Details
For inquiries, call
(973) 736-6333
-
Assessing the Normal Microbiome and Virome of the Lung: A Pilot Study
Trial is open for enrollment.
View All Details
For inquiries, call
(973) 322-2224
-
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)
Trial is open for enrollment.
View All Details
For inquiries, call
(973) 736-6333
-
BiSpectral Index (BIS) Monitoring and Sedation Practices in Critically Ill Mechanically Ventilated Patients: A Single Center, Prospective, Randomized Control Trial
Trial is open for enrollment
View All Details
For inquiries, call
(973) 322-2224
-
Enterprise Vascular Remodeling Devices (VRD)
Trial is open for enrollment.
View All Details
For inquiries, call
(201) 342-2550
-
ESTEEM
- NCT02047097
This Phase IV study follows patients who are newly initiating dimethyl fumarate (Tecfidera) and monitors clinical effectiveness and the incidence of adverse events in routine clinical care.
Type: Observational
Principal Investigator: Andrew Sylvester, MD
Website: ClinicalTrials.gov Identifier: NCT02047097
This study is active, but closed to enrollment.
For inquiries, call (973) 322-7073
-
ESTEEM KETONE SUB-STUDY
An additional sub-study (Ketone Sub- study) to ESTEEM is being offered to approximately 130 patients who are currently enrolled in ESTEEM at ~25 sites in the US in order to assess urine and serum ketones in DMF-treated patients. After enrollment in the sub-study, serum and urine will be collected at each routine visit to measure the serum and urine ketone levels.
Type: Observational
Principal Investigator: Andrew Sylvester, MD
Website: ClinicalTrials.gov Identifier: NCT02047097
This study is active, and open to enrollment for current study subjects.
For inquiries, call
(973) 322-7073
-
FLUENT
- NCT03257358
This Phase IV study aims to characterize how certain immune biomarkers change for MS patients while they are receiving fingolimod (Gilenya) 0.5 mg/day.
Type: Observational
Principal Investigator: Andrew Sylvester, MD
Website: ClinicalTrials.gov Identifier: NCT03257358
This study is active, but closed to enrollment.
For inquiries, call (973) 322-7073
-
Incidence and Risk Factors Associated with Acute Respiratory Failure in Patients after Renal Transplant
Trial is open for enrollment.
View All Details
For inquiries, call
(973) 322-2224
-
Incidence of Thrombotic Complications in Patients with COVID-19 Admitted to Saint Barnabas Medical Center
Trial is open for enrollment.
View All Details
For inquiries, call
(973) 322-2224
-
IV Methylprednisolone for Progressive MS
This study aims to investigate the effectiveness of IV Methylprednisolone (IV MP) at 1g /day for 5 days v. sub-therapeutic doses of IV MP for 5 days in RMS, RRMS, and SPMS DMT-treated MS patients who are experiencing functional decline in the absence of relapses (progressive MS).
Type: Drug Trial
Principal Investigator: Andrew Sylvester, MD
This study is open to enrollment.
For inquiries, call (973) 322-7073
-
OCT Study
Evaluation of Immunomodulator Effects on Retinal Nerve Fiber Layer and Macular Volumes in People with Multiple Sclerosis using Ocular Coherence Tomography
Type: Retrospective Chart review
Principal Investigator: Matthew Tremblay, MD, PhD
Website: IRB Study 20-36
This study is a retrospective data review.
For inquiries, call
(973) 322-7073